DEALS

Zhong Lun Advises Everest Medicines on Top-up Placement

Release time：2025-08-07 Voice Announcements

On August 1, 2025, Everest Medicines Limited (1952.HK) announced the completion of placing of existing shares and top-up subscription of new shares under general mandate; the net proceeds from the subscription amount to approximately HKD 1,553 million.

Zhong Lun Law Firm acted as the PRC advisor to Everest Medicines in this placement. The legal team was led by partners Anthony Zhao and Catherine Chen. Partner Shaun Gao and non-equity partner Roy Zheng took charge of the case with the help of team members including non-equity partner Yun Hu, associates Lindsey Zhang and Ruby Zheng.

Everest Medicines is a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics. Zhong Lun has provided long-term legal services to Everest Medicines, including as its PRC legal advisor for the Hong Kong IPO in 2020.

Previous：Zhong Lun Assists Yijun Capital and Huatai Jijin in Completing Series B1 Investment in Rino.ai Next：Zhong Lun Assists Shanghai SSCI Leading Fund in Partnering with CFT Capital to Establish Juyuan Qixin Fund

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Advises Sleemon on Acquisition of Certain Equity in Jiaxing Milano & Design

Zhong Lun Assists Yijun Capital and Huatai Jijin in Completing Series B1 Investment in Rino.ai

Events

Awards

Zhong Lun Advises Everest Medicines on Top-up Placement